Regina Woods
Psychiatric/Mental Health · Jamestown, KYNPI 1841259272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 619 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$982
- AbbVie$934
- Otsuka America Pharmaceutical, Inc.$827
- plus $5K from 24 others
What the payments were for
- Food & beverage$11,37199%
- Education$1391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 89 | $1,367 |
| Alkermes, Inc. | 53 | $1,178 |
| Teva Pharmaceuticals USA, Inc. | 39 | $1,118 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $982 |
| AbbVie | 65 | $934 |
| Otsuka America Pharmaceutical, Inc. | 44 | $827 |
| Corium, LLC | 47 | $697 |
| Axsome Therapeutics, Inc. | 17 | $608 |
| Sunovion Pharmaceuticals Inc. | 58 | $562 |
| E.r. Squibb & Sons, L.L.C. | 10 | $439 |
| Lundbeck LLC | 22 | $402 |
| Ironshore Pharmaceuticals Inc. | 22 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $274 |
| Tris Pharma Inc | 10 | $183 |
| Vanda Pharmaceuticals Inc. | 12 | $181 |
| Johnson & Johnson | 9 | $175 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $159 |
| Merck | 9 | $154 |
| Almatica Pharma LLC | 6 | $124 |
| Idorsia Pharmaceuticals US Inc | 7 | $122 |
| Sage Therapeutics, LLC | 1 | $121 |
| Noven Therapeutics, LLC | 6 | $112 |
| Biogen | 1 | $97 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| Boehringer Ingelheim | 1 | $85 |
| Janssen Scientific Affairs, LLC | 1 | $78 |
| Collegium Pharmaceutical, Inc. | 4 | $78 |
| Eisai Inc. | 2 | $25 |
| Acacia Pharma Inc | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$499
- INGREZZA$383
- COBENFY$246
- Austedo XR$242
- REXULTI$125
- Auvelity$125
- ARISTADA INITIO$125
- ABILIFY MAINTENA$102
How this compares
$11,510 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 21 | $149,503 |
| IngrezzaValbenazine Tosylate | 15 | $114,126 |
| RexultiBrexpiprazole | 25 | $35,348 |
| CaplytaLumateperone Tosylate | 19 | $32,572 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $22,578 |
| TrintellixVortioxetine Hydrobromide | 19 | $15,892 |
| VraylarCariprazine Hcl | 11 | $14,739 |
| BelsomraSuvorexant | 33 | $14,177 |
| Lurasidone Hcl | 23 | $10,146 |
| QuviviqDaridorexant Hcl | 14 | $6,805 |
| Asenapine Maleate | 17 | $6,617 |
| Clozapine | 48 | $4,725 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 82 | $3,412 |
| Aripiprazole | 41 | $2,262 |
| Gabapentin | 170 | $2,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,118 | $149,50321 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,367 | $114,12615 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $827 | $35,34825 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $982 | $32,57219 claims |
| Axsome Therapeutics, Inc.Auvelity | $608 | $22,57819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $274 | $15,89219 claims |
| AbbVieVraylar | $934 | $14,73911 claims |
| MerckBelsomra | $154 | $14,17733 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $122 | $6,80514 claims |
| Almatica Pharma LLCSertraline Hcl | $124 | $23831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Jamestown
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.